GLP-1 Decade Reshape
mike Test@mike2
+4.2%
since Sep 12
The idea
I believe GLP-1 drugs are rewiring food, retail, and healthcare for the next decade, not just a passing trend. So this basket spreads across the whole chain: the two dominant drugmakers, the manufacturers solving the capacity bottleneck, the distributors moving the volume, consumer brands catching the new appetite, and the surgeons benefiting downstream. I keep a slice in cash and avoid concentrating in any single name, planning to hold for years since this is a slow structural shift, not a quarterly story.
What it owns
- Demand outruns supply, so companies making pens, cartridges, and filling capacity become the constraint that gets paid regardless of which drug succeeds. · West Pharmaceutical ServicesIt makes elastomer components and delivery systems inside injector pens, so every pen puts money in its pocket regardless of which drug wins., Thermo Fisher ScientificIt sells fill-finish capacity to drugmakers, and the bottleneck right now is filling syringes and pens, not patient demand., DanaherIt sells bioprocessing equipment and consumables drugmakers need as they build GLP-1 production capacity., Becton DickinsonIt is the volume play on needles and pen injection at massive scale as tens of millions of weekly injections drive steady needle demand., Stevanato GroupIt makes glass cartridges and pen parts that GLP-1 doses ship in and is expanding plants specifically for this demand.26%
- The companies that own GLP-1 drugs capture direct value from the shift toward weight loss treatment. · Eli LillyIt owns Zepbound and Mounjaro, the fastest-growing GLP-1 drugs, and the take depends on it keeping prescriptions climbing and building manufacturing capacity throughout the decade., Novo NordiskIt invented this drug category and the take counts on it staying one of the two dominant makers rather than losing share to newer competitors., AmgenIts obesity pipeline, especially a monthly injectable candidate, could capture share if trials keep delivering results., Viking TherapeuticsIt is the small, risky bet that a pill form of GLP-1 opens the market to people who will not inject, with no approved product yet.24%
- People on GLP-1s eat less junk and spend more on protein, fitness, and clothing as their bodies change. · BellRing BrandsPeople on GLP-1s eat less but need more protein to keep muscle, and its Premier Protein shakes sit directly in that shift., Planet FitnessIt is the cheap, beginner-friendly gym that catches first-time members created by weight loss., Sprouts Farmers MarketIt is the grocer built for smaller, protein-heavy, lower-sugar shopping baskets, which is exactly how GLP-1 users shop., Lululemon AthleticaSignificant weight loss forces a wardrobe rebuild, and it is the premium brand for people newly investing in an active lifestyle., Simply Good FoodsIt owns high-protein and low-sugar snack brands that match how GLP-1 users graze.21%
- Record drug volume must move physically and be prescribed, so distributors and telehealth platforms take a cut of every dose. · McKessonIt gets paid to move drugs, and GLP-1s are now a huge share of US prescription volume growth., CencoraIt is the second toll collector on drug distribution with the same logic as other distributors: record GLP-1 volume flows through its warehouses., Hims & Hers HealthIt is the bet that significant GLP-1 access happens through telehealth rather than a doctor's office.13%
- Millions of newly lighter patients become eligible for joint replacements they were previously denied. · Zimmer BiometPatients who lose weight finally qualify for knee and hip replacements they have been postponing., StrykerPlenty of people are too heavy to qualify for joint replacement, and GLP-1 weight loss moves them into the surgery pipeline.8%
- Cash8%